| Dr Matthew Samuel Carlton Gutierrez, PHARMD | |
|
100 Lincoln Village Cir, 205, Larkspur, CA 94939-1621 | |
| (951) 529-4222 | |
| Not Available |
| Full Name | Dr Matthew Samuel Carlton Gutierrez |
|---|---|
| Gender | Male |
| Speciality | Pharmacist - Pharmacotherapy |
| Location | 100 Lincoln Village Cir, Larkspur, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619349552 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1835P1200X | Pharmacist - Pharmacotherapy | 71369 (California) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Matthew Samuel Carlton Gutierrez, PHARMD 100 Lincoln Village Cir, 205, Larkspur, CA 94939-1621 Ph: (951) 529-4222 | Dr Matthew Samuel Carlton Gutierrez, PHARMD 100 Lincoln Village Cir, 205, Larkspur, CA 94939-1621 Ph: (951) 529-4222 |
News Archive
BDI Pharma, Inc. (BDI), the fastest growing national distributor of biotech therapies, announced today the introduction of SecuriVAX(SM) (www.securivax.com), an online supply solution providing the healthcare community a one-stop source for a wide variety of vaccines.
The discovery by researchers from the Walter and Eliza Hall Institute of a molecule that is key to malaria's 'invisibility cloak' will help to better understand how the parasite causes disease and escapes from the defenses mounted by the immune system.
TeleTracking Technologies, Inc. was named 'Tech Titan of the Year' for the second straight year at the Pittsburgh Technology Council's Tech 50 Awards, which annually honors the most successful and innovative companies in southwestern Pennsylvania's burgeoning technology sector.
Data from the landmark HORIZONS-AMI clinical trial demonstrated that the administration of the anticoagulant medication bivalirudin enhanced survival compared to the use of heparin plus a glycoprotein (GP) IIb/IIIa inhibitor in heart attack patients undergoing angioplasty after 3 years. Use of a drug-eluting stent was also shown to be more effective than a bare-metal stent, with equivalent safety.
Ligand Pharmaceuticals Incorporated announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc.. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand (through its CyDex Pharmaceuticals subsidiary) originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006.
› Verified 6 days ago
Mrs. Rebecca Lofholm, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Bon Air Rd Ste 130, Larkspur, CA 94939 Phone: 415-924-2454 Fax: 415-924-1015 | |
Donald L Lazzaretto, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Bon Air Rd, Suite 130, Larkspur, CA 94939 Phone: 415-924-2454 Fax: 415-924-1015 | |
Ms. Brigette Lofholm, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Bon Air Rd, Suite 130, Larkspur, CA 94939 Phone: 415-924-2454 Fax: 415-924-1015 | |
Dr. Mario Santi, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2 Bon Air Rd, Suite 130, Larkspur, CA 94939 Phone: 415-924-2454 Fax: 415-924-1015 | |
Mr. Ernie Khim Jr., Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 570 Magnolia Ave, Larkspur, CA 94939 Phone: 415-924-6738 |